Lumida
/ACRS
⌘K
Aclaris Therapeutics Inc

Aclaris Therapeutics Inc

ACRS
$5.32USD↓-3.36%-0.18 today

MARKET CAP

783.1M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$5 – $6

52W RANGE

$2
$7

AI Summary

Stalk
StalkMedium

ACRS remains in a Stage 2 advancing regime with higher highs and rising EMAs intact. The medium-term bias is bullish, reinforced by price above key moving averages despite exhaustion signals. Near-term, a Bullish Exhaustion pattern and RSI pullback indicate momentum is easing. Price is consolidating just above the 9/20 EMA band, making timing unfavorable now. Wait for a pullback into rising EMA support before initiating any long exposure.

  • ↑FDA Fast Track designation accelerates modzatinib approval pathway.
  • ↑Analysts rate Buy with $11.33 average target (~60% upside).
  • ↓Net margin –921% and earnings yield –1.25 reflect deep losses.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is an emerging biotechnology company primarily focused on developing novel therapies for dermatological indications. The company is gaining attention in the biopharmaceutical sector, particularly with its investigational therapy modzatinib (ATI-2138), which targets conditions such as lichen planus. Positioned within the broader trend of increased investment in dermatological treatments, Aclaris is positioned as a company that could experience significant growth, especially if its therapeutics receive regulatory approval and meet clinical efficacy endpoints.

Bull says

  • ↑FDA Fast Track designation accelerates modzatinib approval pathway.
  • ↑Analysts rate Buy with $11.33 average target (~60% upside).
  • ↑Q2 revenue beat: $1.63M vs. $1.38M estimate.
  • ↑13F Ownership high, signaling strong institutional backing.
  • ↑Cash runway extends to end-2028, supporting operations.
  • ↑Dividend yield 0.5% adds shareholder value support.

Bear says

  • ↓Net margin –921% and earnings yield –1.25 reflect deep losses.
  • ↓Leverage score indicates high debt, limiting financial flexibility.
  • ↓Negative growth factor suggests declining revenue expansion prospects.
  • ↓Volatility score and 8% one-day drop highlight stock swings.
  • ↓Negative revisions signal potential further analyst downgrades.
  • ↓ROE –61.6% underscores capital loss issues.

Investment themes with ACRS

Pharmaceuticals↑ +0.79%

Drug development driving global healthcare solutions

LLY · JNJ · MRK

Earnings Call · Q1 2023 · Mgmt. Guidance

Updated 08-10-2026neutral

Transcript signals

Bull points

  • During the first quarter of this year, we completed and reported the top-line results of our Phase 2A trial of ATI450-NHS.
  • Importantly, this trial further expanded our experience and understanding of ATI450.
  • Importantly, we continue to execute on these programs in a fiscally prudent and conservative manner.

Bear points

  • However, we believe it is likely that the disease is perhaps driven more locally in the skin than through systemic pathways.
  • CRP levels were reduced to the upper limit of normal after seven days of dosing, and this inhibition was retained through study completion at 12 weeks in both the HS and RA 2A studies.
  • we believe correspond to positive efficacy readouts from our completed RA trial, however, not HS.
Read full transcript analysis ›